Abstract
To clarify the degree of parathyroid dysfunction in end-stage renal failure, sigmoidal relationship between serum Ca2+ and intact-PTH was evaluated in vivo in 47 hemodialysis (HD) patients including 12 diabetics. Patients were divided into 3 groups, 9 who had been just introduced to HD (0 years), 31 who were on maintenance HD for 2.5 to 16.2 years without significant secondary hyperparathyroidism (2nd HPT), and 7 who suffered from severe 2nd HPT for 8.5 to 15.3 years on HD. Additional 4 patients who were treated with HD or hemodiafiltration because of acute hepatic failure with normal renal function were selected for control. Sigmoidal curve (SC) in patients with non-diabetics on 0 years on HD was significantly deviated to upper and right direction. Similarly, the set point of calcium (SP) in non-diabetics was deviated to the right (higher calcium level). These abnormalities were more pronounced as the length of HD duration increased. However, these parathyroid dysfunction was not obvious in diabetic patients. In severe 2nd HPT, SC and SP were remarkably deranged. Mean SP in these patients was 1.22 mmol/l, and 1.26 mmol/l in 3 patients who required parathyroidectomy after the study. These results indicate that the earlier treatment to prevent 2nd HPT would be necessary from conservative stage of renal failure in non-diabetic population.
Similar content being viewed by others
References
Brown EM, Wilson RE, Eastman RC, et al. Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal faiure. J Clin Endocrinol Metab 54: 172–179, 1982
Birnbaumer M, Schneider A, Palmer D, et al. Secretion of parathyroid hormone by abnormal human parathyroid glands in vitro. J Clin Endocrilol Metab 45: 105–113, 1977
Brown EM. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 56: 572–581, 1983
Dunlay R, Rodrigues M, Felsenfeld AJ, et al. Direct inhibitory effect of parathyroid function (sigmoidal curve) in dialysis. Kidney Int 36: 1093–1098, 1989
Slatopolsky E, Weerts C, Thielan J, et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 74: 2136–2143, 1984
Tsukamoto Y, Nomura Y, Takahashi Y, et al. The oral 1,25-dihydroxy vitamin D3 pulse therapy in hemodialysis patients with severe secondary hyperparathyroidism. Nephron 57: 23–28, 1991
Akizawa T, Koshikawa S, Ogura Y, et al. Oral puse of 1α OHD suppresses PTH in refractory patients with secondary hyperparathyroidism (abstract). Proceedings, Singapore symposium on renal blood disease, July 1990
Pabico RC, Rivero AJ, Mckenna AB, et al. Parathyroid hormone in patients with diabetes mellitus and end-stage renal disease on chronic hemodialysis. Proc EDTA, 221–226, 1982
McNair P, Christensen MS, Madsbad S, et al. Hypoparathyroidism in diabetes mellitus. Acta Endocrinol 96: 81–86, 1981
Morrisey J, Rothstein M, Slatopolsky E, et al. Suppression of parathyroid hormone secretion by aluminum. Kidney Int 23: 699–704, 1983.
Sugimoto T, Ritter C, Morrisey J, et al. Effects of high concentration of glucose on PTH secretion in parathyroid cells. Kidney Int 37: 1522–1527, 1990
Author information
Authors and Affiliations
About this article
Cite this article
Kinugasa, E., Akizawa, T. & Koshikawa, S. Parathyroid function in end-stage penal failure. J Bone Miner Metab 11, S53–S58 (1993). https://doi.org/10.1007/BF02383844
Issue Date:
DOI: https://doi.org/10.1007/BF02383844